ArticlePostepy psychiatrii neurologii2025
Cognitive dysfunction and atrophic changes of selected cerebral structures in patients with relapsing-remitting multiple sclerosis.
Article in Postepy psychiatrii neurologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to compare the results of the selected neuropsychological tests in patients with newly diagnosed multiple sclerosis (MS) in relation to the selected volumetric brain measurements assessed by magnetic resonance imaging (MRI). Methods: The study group consisted of 76 patients with newly diagnosed MS. Each patient underwent functional assessment using the Multiple Sclerosis Functional Composite Battery (MSFC), the Kurtzke Expanded Disability Status Scale (EDSS) and evaluation of cognitive function using a battery of tests. The patients also underwent head MRI with the assessment of the volume of the cortex and subcortical structures. Psychological assessment and head MRI were performed before initiating immunomodulatory treatment and after 12 months of follow-up. Results: Positive correlations were obtained between partial brain volume and Paced Auditory Serial Addition Test (PASAT3"), total volume of grey matter and Selective Reminding Test (SRT) and Brief Visuospatial Memory Test - Recognition Discrimination (BVMT-RD), the cortical volume and PASAT3", SRT, Brief Visuospatial Memory Test - Revised (BVMT-R) and BVMT-RD in assessing the relationship between atrophic changes in brain structures and the severity of cognitive impairment in MS patients at baseline. Significant relationships were found between the volumetric parameters and SRT-D. Positive correlations were obtained between the volumetric parameters and the scores of PASAT3". No significant correlations were found between the severity of cognitive dysfunction and the duration of MS. Conclusions: There is a clear need to evaluate particular cognitive domains in patients with MS as early as from the onset of the disease, and to perform long-term follow-up of these changes. The assessment of the two most frequently impaired cognitive domains could be a screening indicator for detecting cognitive dysfunction in MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.